Results 31 to 40 of about 94,936 (269)

Maternal and Neonatal Complications Associated with Breast Cancer Systemic Treatments-A VigiBase Disproportionality Analysis Study. [PDF]

Clin Pharmacol Ther
Pregnancy‐associated breast cancer (PrBC) presents therapeutic challenges. Understanding maternal–fetal safety of systemic anticancer therapies is critical. We performed a case/non‐case disproportionality analysis using the WHO global pharmacovigilance database up to January 2024, to evaluate maternal–fetal outcomes associated with breast cancer (BC ...
Kabirian R, Jochum F, Dumas E, Coussy F, Bihan K, Lebrun-Vignes B, Pistilli B, Benderra MA, Selleret L, Chouchana L, Reyal F, Hamy AS, Gougis P.   +12 more
europepmc   +2 more sources

The effects of docetaxel and/or captopril in expression of TGF-β1, MMP-1, CTGF, and PAI-1 as markers of anterior urethral stricture in an animal model

Therapeutic Advances in Urology, 2020
Background: Treatment of urethral trauma is currently done after urethral stricture occurs. Stricture therapy after occurrence gives unsatisfactory success rates. Several genes, such as transforming growth factor beta 1 (TGF-β1), matrix metalloproteinase 
Wikan Kurniawan, Marsetyawan Heparis Nur Ekandaru Soesatyo, Teguh Aryandono   +2 more
doaj   +1 more source

Ritonavir inhibits intratumoral docetaxel metabolism and enhances docetaxel antitumor activity in an immunocompetent mouse breast cancer model [PDF]

, 2016
Docetaxel (Taxotere(®) ) is currently used intravenously as an anticancer agent and is primarily metabolized by Cytochrome P450 3A (CYP3A). The HIV protease inhibitor ritonavir, a strong CYP3A4 inhibitor, decreased first-pass metabolism of orally ...
Schellens, Jan H M, Song, Ji Ying, Jan H.M. Schellens, Rottenberg, Sven, Beijnen, Jos H., Lagas, Jurjen S, Sven Rottenberg, Lagas, Jurjen S., Hendrikx, Jeroen J M A, Jurjen S. Lagas, Song, Ji-Ying, Pharmacoepidemiology and Clinical Pharmacology, Ji‐Ying Song, Hilde Rosing, Schinkel, Alfred H, Sub Clinical Pharmacology, Jeroen J.M.A. Hendrikx, Rosing, Hilde, Jos H. Beijnen, Beijnen, Jos H, Schinkel, Alfred H., Alfred H. Schinkel   +21 more
core   +3 more sources

Combination treatment of docetaxel with caffeic acid phenethyl ester suppresses the survival and the proliferation of docetaxel-resistant prostate cancer cells via induction of apoptosis and metabolism interference

Journal of Biomedical Science, 2022
Background Docetaxel has been approved by USFDA as a first-line treatment for castration-resistant prostate cancer (CRPC) patients. Patients receiving androgen deprivation therapy along with docetaxel result in superior survival, lower serum prostate ...
Yu-Ke Fu, Bi-Juan Wang, Jen-Chih Tseng, Shih-Han Huang, Ching-Yu Lin, Ying-Yu Kuo, Tzyh-Chyuan Hour, Chih-Pin Chuu   +7 more
doaj   +1 more source

A Long Noncoding RNA, GAS5 Can Be a Biomarker for Docetaxel Response in Castration Resistant Prostate Cancer

Frontiers in Oncology, 2021
While functional studies of long noncoding RNAs (lncRNAs) have mostly focused on how they influence disease diagnosis and prognosis, the pharmacogenomic relevance of lncRNAs remains largely unknown.
Yuting Shan, Yingbo Huang, Adam M. Lee, Joshua Mentzer, Alexander Ling, R. Stephanie Huang   +5 more
doaj   +1 more source

Endothelial Cells Promote Docetaxel Resistance of Prostate Cancer Cells by Inducing ERG Expression and Activating Akt/mTOR Signaling Pathway

Frontiers in Oncology, 2020
Docetaxel is a first-line chemotherapy for the treatment of patients with castration-resistant prostate cancer (CRPC). Despite the good initial response of docetaxel, drug resistance will inevitably occur.
Wenhao Zhou, Yiming Su, Yu Zhang, Bangmin Han, Haitao Liu, Xiaohai Wang   +5 more
doaj   +1 more source

Real-World Treatment Patterns in Men with Castration- Resistant Prostate Cancer Receiving Docetaxel

Journal of Health Economics and Outcomes Research, 2015
# Background Docetaxel has been a standard of care for castration-resistant prostate cancer (CRPC) in the United States since 2004, yet little has been reported on its patterns of use in routine practice.
Keith L. Davis, Benjamin Gutierrez, Teresa Zyczynski, James A. Kaye   +3 more
doaj   +1 more source

Use of in vitro human keratinocyte models to study the effect of cooling on chemotherapy drug-induced cytotoxicity [PDF]

, 2014
A highly distressing side-effect of cancer chemotherapy is chemotherapy-induced alopecia (CIA). Scalp cooling remains the only treatment for CIA, yet there is no experimental evidence to support the cytoprotective capacity of cooling. We have established
van den Hurk, Corina J., Komen, Manon M., Hussain, Omar, Dunnill, Christopher, Georgopoulos, Nikolaos T., Al-Tameemi, Wafaa, Collett, Andrew   +6 more
core   +1 more source

Paclitaxel induces NM2‐dependent cellular contraction through GEF‐H1 dissociation from microtubules and RhoA/ROCK activation in cancer cells

Molecular Oncology, EarlyView.
Taxanes are widely used chemotherapeutics whose effects on cellular mechanics remain poorly understood. We show that paclitaxel induces rapid cellular contraction by promoting GEF‐H1 dissociation from microtubules and non‐muscle myosin II activation through RhoA/ROCK.
Gloria Asensio‐Juárez, Rafael Pérez‐Díaz, Hugo Ramos‐Solano, Marina Garrido‐Casado, Vanessa C. Talayero, Miguel Vicente‐Manzanares   +5 more
wiley   +1 more source

Clinical Impact of Gleason Pattern 5 on Doublet Versus Triplet Therapy in Metastatic Hormone-Sensitive Prostate Cancer. [PDF]

Prostate
ABSTRACT Background Upfront treatment intensification with androgen deprivation therapy (ADT) plus an androgen receptor pathway inhibitor has become a standard approach for metastatic hormone‐sensitive prostate cancer (mHSPC). However, prognosis remains poor for some patients despite second‐generation androgen receptor antagonist‐based doublet therapy.
Fujimoto S, Morita T, Yamamoto Y, Inamoto T, Tamura K, Yoshikawa Y, Maenosono R, Takeuchi A, Takahara K, Sugiyama S, Komura K, Yanagisawa T, Fukuokaya W, Kimura T, Fujita K.   +14 more
europepmc   +2 more sources